
PulsHeart: IHU Liryc Start-up
A spin-off from a world-renowned research institute
Mission
To develop ready-to-market non-invasive medical systems to assess the risk of sudden cardiac death.
PulsHeart is hosted at Liryc as part of a scientific collaboration.
Liryc is a unique institute in the world as it is entirely dedicated to cardiac rhythm disorders with the primary mission of preventing, diagnosing and treating these cardiac rhythm diseases.


History


Founder
Michel Haïssaguerre
Professor Michel Haïssaguerre is a world-renowned cardiac electrophysiologist whose work has shaped modern arrhythmia treatment. He invented the first multi-electrode catheters to precisely map cardiac signals in different heart walls. He demonstrated that abnormal activity in the pulmonary veins triggered atrial fibrillation and pioneered catheter-based pulmonary vein isolation, the major breakthrough that remains the foundation of current ablation therapies (1 million patients treated annually). He performed the first mappings of ventricular fibrillations responsible for SCD and the first curative treatments.
He headed the Department of Cardiology — Electrophysiology and Pacing at Hôpital Cardiologique du Haut-Lévêque (Bordeaux University Hospital) and founded and chaired the IHU Liryc research institute in 2011, which now has more than 200 researchers.
Professor Haïssaguerre has received numerous major scientific distinctions worldwide, including the ESC Gold Medal, for his exceptional contributions to cardiac rhythmology. He is a member of the French National Academy of Medicine and the Academy of Sciences, and the author of more than 900 peer-reviewed publications in leading medical or cardiology journals.

Leadership team

Sylvain Fanier
President
Sylvain Fanier is a seasoned medical innovation executive with over three decades of experience in concept-to-market developments in the healthcare sector. He drives breakthrough innovations and sits on the boards of medtech and biotech companies. Holder of an MSc from Université Paul Sabatier and an EMBA from ESSEC, he has solid operational and strategic success experience with medical devices and biotech, particularly in cardiology (Cordis, Biosense-Webster JnJ, Bard EP, Cardioinsight, Cathpax by Lemerpax, Naogen Pharma).

François De Guio
General Manager / COO
François De Guio is an experienced MedTech sector leader specializing in operations management and clinical research related to innovative medical devices. He has held executive positions, including Director of Clinical Affairs at Idoven (AI-assisted cardiology), Head of Scientific Evidence at Intuitive Surgical (robotic surgery), and Senior Researcher at Medimaps (medical imaging). Previously, he was an academic researcher in brain imaging (Inserm, CEA). He holds an engineering degree in signal/image processing (INSA Lyon) and a PhD in medical physics, and is the author of over 50 scientific publications.

Hans-Jakob Schmid
CTO
Hans-Jakob Schmid is an experienced R&D manager and ECG signal processing specialist. Former Vice President, R&D Director at Schiller AG, and President of Schiller Médical SAS, he combines in-depth expertise in signal processing, especially electrocardiogram algorithms, with the development, production, and marketing of products for diagnostic and monitoring devices, and defibrillators. He has written technical articles on automated ECG processing and actively participates in standards committees, contributing to the development of technical standards and guidelines for ECG devices and algorithms and for monitoring devices.

Laurent Launay
Director of Engineering
Laurent Launay is a technical director with 30 years of experience in developing innovative medical devices. He held the position of Vice President of Engineering at Volta Medical and several R&D and engineering management positions in health technology companies, including GE Healthcare. A graduate of École Centrale Paris and holder of a PhD in computer science, he brings extensive expertise in transforming complex research into commercial medical devices.

Tanner Carbonati
Director of Signal Processing
Tanner Carbonati is a signal processing and machine learning engineer, specializing in deep learning and cardiac electrophysiology. He has expertise in ECG analysis, sudden cardiac death, and arrhythmia risk prediction, making him a key contributor to the development of AI-based cardiac diagnostic solutions.

Clément Mayeur
Chief Financial Officer
Clément Mayeur specializes in start-up financial management. He began his career in mergers and acquisitions in the audiovisual sector (Orange Sport, TF1) then joined an international group in financing (Dream Yacht Charter). He then became a shared CFO and specialized in biotech medtech. He is notably CFO of Naogen Pharma and Atonco. With over 15 years of experience in corporate financial management, Clément brings his financial expertise in management and dilutive and non-dilutive financing. Clément is a graduate of Université Paris Dauphine-PSL, University of Reading, EDHEC Business School, and holds a postgraduate degree from Université Paris Sorbonne.
Advisors

K. Nademanee
Dr. Nademanee is an internationally recognized electrophysiologist. He is a Distinguished Professor of Medicine at Chulalongkorn University, Thailand, and Director of the Center of Excellence in Arrhythmia Research at Chulalongkorn University, as well as the Heart Institute at Bumrungrad International Hospital. He received an honorary Doctor of Medicine degree from Mahidol University and was appointed a Knight Grand Commander of the Most Illustrious Order of Chula Chom Klao, a prestigious Royal Thai decoration conferred by King Bhumibol Adulyadej. His clinical and research work focuses on atrial fibrillation, ventricular arrhythmias, electrical storm management, and catheter ablation therapies. He has authored numerous influential peer-reviewed publications, including seminal work on electrical storm treatment, arrhythmogenic substrate ablation in J-wave syndromes, and electrogram-guided ablation strategies for atrial fibrillation. He was the first to identify the right ventricular epicardium—particularly the right ventricular outflow tract (RVOT)—as a key arrhythmogenic substrate in Brugada syndrome. He continues to lead and publish clinical studies, including investigations of catheter ablation for Brugada syndrome and refractory ventricular tachycardia.

Charu Ramanathan
Charu Ramanathan is a medical technology entrepreneur and biomedical engineering inventor, whose doctoral work led to the clinical translation of non-invasive electrocardiographic imaging (ECGI). She co-founded CardioInsight, the company behind high-density non-invasive cardiac mapping systems, which was acquired by Medtronic in 2015. Holder of a PhD in biomedical engineering from Case Western Reserve University, she has since founded and advised several digital health and MedTech companies, including Vitalxchange. She continues to bridge advanced technical research, product strategy, and clinical adoption, actively contributing to the evolution of medical innovation.

Rémi Dubois
Rémi Dubois is a professor and senior researcher at IHU Liryc (Electrophysiology & Heart Modelling Institute, Bordeaux), where he leads the Signal Processing team and co-leads the Connected Health department. His work lies at the interface between instrumentation, biomedical signal processing, and non-invasive cardiac mapping. He develops tools to extract and localize electrical activity from surface recordings to better understand and treat cardiac arrhythmias. He is author or co-author of over 200 peer-reviewed scientific publications and regularly contributes to translational projects and training programs conducted by IHU Liryc.

Olivier Bernus
Olivier Bernus is a professor at the University of Bordeaux, current Scientific Director of IHU Liryc (Institute for Cardiac Rhythm Diseases), and head of the Cardiac Electrophysiology team at the Bordeaux Cardio-Thoracic Research Center (CRCTB U1045). His work combines experimental optical mapping, computational cardiac modeling, and high-resolution imaging to study the mechanisms of arrhythmias, ventricular fibrillation and sudden cardiac death, and translate these insights into diagnostic and therapeutic innovations. He is co-author of over 150 scientific publications and has coordinated several major projects, both nationally and internationally. He is currently involved in various translational research projects and training programs, and regularly contributes to international conferences on arrhythmias.

Karim Benali
Dr. Karim Benali is a cardiac electrophysiologist based at Saint-Étienne University Hospital, actively collaborating on clinical and research work with IHU Liryc / Hôpital Haut-Lévêque (Bordeaux). His clinical activity focuses on ventricular arrhythmias, electrical storm management, and advanced ablation therapies. He also participates in research on sudden cardiac death and idiopathic ventricular fibrillation. He is author and co-author of numerous articles published in peer-reviewed journals and regularly speaks at international conferences on cardiac rhythm disorders.















